Stock screener

ANRO

Conviction 72HealthcareScan · Thu, Sep 24, 2026

Alto Neuroscience, Inc. (ANRO) closed at $27.13 (-1.35%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 31, RS Rating 99, -26.0% from its 52-week high, +63.5% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

ANRO$27.13-1.35%
ResistanceSupportVol 14
63 bars
Vol MA14 1.11M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Alto Neuroscience, Inc.PHARMACEUTICAL PREPARATIONSwww.altoneuroscience.com ↗
Price27.13
Change-1.35%
Gap+0.85%
Rel volume13.92×
Avg volume897.57K
Avg $ vol27.08M
SMA 2032.67
SMA 5031.03
SMA 20023.38
Price vs 50-12.56%
Price vs 200+16.03%
MA stackmixed
50/200 cross—
Supertrenddown · 33.11
RSI (14)31
MACD hist-0.82
MACD cross—
Stoch %K / %D7 / 10
ADX (14)32
+DI / −DI12 / 27
RSI divergenceBearish
MACD divergenceBearish
ATR %7.24%
ADR %5.76%
52w high36.64
52w low3.80
From 52w high-25.96%
Above 52w low+613.95%
New 52w highNo
SqueezeOff
Bollinger width35.90%
%B0.03
Donchian pos6.56%
Donchian high37.39
Donchian low26.41
AVWAP (52w high)30.57
vs AVWAP high-11.25%
AVWAP (52w low)15.94
vs AVWAP low+70.23%
OBV trendDown
Chaikin MF (20)-0.24
Today vs 20d13.92×
Avg vol (14d)1.11M
Avg vol (20d)897.57K
Avg $ vol (20d)27.08M
Market cap1.06B
RS Rating99 / 99
RS 3m (vs SPY)+2.74%
RS 6m (vs SPY)+14.44%
RS line new highNo
Trend template6/8
Technical rank57.1
1 week-12.43%
1 month-25.28%
3 months+7.23%
6 months+31.25%
1 year+560.10%
YTD+63.53%
P/E-16.84
P/B4.86
P/S—
P/FCF-20.56
EPS-2.19
Div yield—
ROE-28.84%
ROA-24.89%
Debt/Eq0.07
Current14.85
EV/EBITDA-12.71
Gross margin—
Net margin—
Rev growth—
EPS growth-2.94%
Price target44.00
Target upside62.18%
Analyst ratingBuy
Institutional79.17%
Ent. value837.09M
Revenue—
Net income-27.64M
Gross profit—
Free cash flow-51.79M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNYSE
Shares out35.09M
Employees68
ListedFri, Feb 2, 2024
Free float23.95M
Float %75.0%
Short interest3.84M
Days to cover8.1d
Short volume60.2%
Squeeze score86 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.65 vs −$0.71
Last surprise+8.4% beat
Setup gradeB
Conviction72 / 100
Pattern quality—
Tech rank57.1 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance37.44
Support26.60
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Signal lifecycle

How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.

  1. Setting up
    Jul 10 – Aug 11
    2 scans
  2. Breaking out now
    Aug 12
    1 scan
  3. Broke out
    Aug 13 – Aug 20
    6 scans
  4. Setting up
    Aug 31 – Sep 3
    3 scans

Recent news

Congress activity

Disclosed STOCK Act trades in ANRO

All disclosures →
No recent disclosed trades by Congress in ANRO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ANRO

InsiderSideShares
Miller Andrew Craig
Director · Stock Option (right to buy) · 2026-05-27
Grant26K
Etkin Amit
PRESIDENT AND CEO · Common Stock · 2026-05-14
Gift400K
Cox Christopher Nixon
Director · Stock Option (right to buy) · 2026-05-12
Grant10.96K
Sanchez Ramiro
Director · Stock Option (right to buy) · 2026-05-12
Grant10.96K
Manji Husseini
Director · Stock Option (right to buy) · 2026-05-12
Grant10.96K
Dreyfus Andrew
Director · Stock Option (right to buy) · 2026-05-12
Grant10.96K
York Gwill
Director · Stock Option (right to buy) · 2026-05-12
Grant10.96K

SEC filings

EDGAR filings in ANRO · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.